News
Zacks Investment Research on MSN21h
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
Novo keeps China manufacturing investments rolling with $112M for new quality testing lab in Tianjin
A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.
Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth $11. ...
Novo helped to create a new market that should provide over 20% growth in the medium term. At 1.5x PEG I arrive at YE25 price target of $162. Read more on NVO stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback